Zinger Key Points
- Avicanna secured a patent for its deep penetrating topical cannabinoid composition and its methods for treating musculoskeletal pain
- The patented technology enhances the transdermal diffusion of cannabinoids through the epidermis and into sub-epidermal layers.
- China’s new tariffs just reignited the same market patterns that led to triple- and quadruple-digit wins for Matt Maley. Get the next trade alert free.
Avicanna Inc. AVCNF, a leading biopharmaceutical company specializing in plant-derived cannabinoid-based products, has announced the issuance of U.S. Patent No. US 20230025693A1 by the United States Patent and Trademark Office (USPTO). This patent covers Avicanna's deep penetrating topical cannabinoid composition and methods for treating musculoskeletal inflammation and pain.
"We are very happy with the issuance of another USPTO patent, this time on transdermal topical technology that has been a significant part of our research & development, R&D and clinical efforts," stated Aras Azadian, CEO of Avicanna. "This technology was created through years of development, including AI-guided prediction modeling, pre-clinical trials and real-world evidence, and is part of our RHO Phyto commercial portfolio. We look forward to the incorporation of our patented technologies as we move forward to further evolving our pipeline, particularly those that target musculoskeletal pain and inflammation."
A New Frontier In Pain Management
Traditional pain relief methods often come with significant side effects, including those impacting the gastrointestinal, central nervous and cardiovascular systems. Avicanna's newly patented technology offers an alternative through a topical formulation that delivers active ingredients directly into deep tissue layers, potentially providing better efficacy with fewer side effects.
As the company stated, the significance of this technology was highlighted in a real-world evidence study where participants reported improvements in symptoms and quality of life related to musculoskeletal pain and inflammation. Seventy-one patients participated in the study, completing baseline testing and follow-up assessments after one month. The study evaluated the patient-reported efficacy of the RHO Phyto CBG Transdermal Gel, which contains 2% cannabidiol (CBD) and 1% cannabigerol (CBG), across a range of conditions including arthritis, osteoarthritis, rheumatoid arthritis, fibromyalgia, and post-surgical pain.
About The Technology
The patented technology enhances the transdermal diffusion of cannabinoids through the epidermis and into sub-epidermal layers. This is accomplished by encapsulating cannabinoids within a nano- and micro-metric emulsion system with penetration enhancers, which are then stabilized in a gel matrix. The water-based gel leverages Avicanna's proprietary deep tissue technology, combining cannabinoids with synergistic terpenes and natural excipients to maximize therapeutic outcomes.
Cover image made with AI
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!